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Abstract
Purpose The aim of this study is to determine the pharmaco-
kinetics (PK) and pharmacodynamics (PD) of a single 12.5- or
25-mg dose of alogliptin, a dipeptidyl peptidase-4 (DPP-4)
inhibitor, in pediatric (children and adolescents) and adult
subjects with type 2 diabetes mellitus (T2DM).
Methods A randomized, open-label, multicenter study was
conducted in pediatric and adult subjects. Subjects in two
pediatric groups (children and adolescents) were randomized
1:1 to receive a single oral dose of alogliptin 12.5 or 25 mg,
respectively; all gender- and race-matched adult subjects re-
ceived alogliptin 25 mg. Blood and urine samples were col-
lected at prespecified time points for PK/PD analyses. A PK/
PD model was developed using data from the study for
steady-state simulations. Safety was also assessed.
Results In pediatric subjects receiving the 25-mg dose, the
mean alogliptin peak plasma concentrations (Cmax) and
AUC0-inf values were 26 and 23% lower, respectively, than
in adults receiving the 25-mg dose, but maximum observed
DPP-4 inhibition effect (Emax) and AUEC0–24 values were
similar to those in adults. In pediatric subjects receiving the
12.5-mg dose, the mean alogliptin Cmax and AUC0-inf values
were 58 and 54% lower, respectively, than those in adults,
hence Emax and AUEC0–24 values were also lower by 11 and
17%, respectively. The PK/PD model simulated data were
consistent with study results. No safety concern was found.
Conclusions A 25-mg dose of alogliptin in pediatric subjects
achieved alogliptin exposures and DPP-4 inhibition similar to
those in adult T2DM patients without safety concerns; there-
fore, this dose is recommended for a pediatric phase 3 trial.
Keywords Alogliptin . Pharmacokinetics .
Pharmacodynamics . Pediatric patients . DPP-4 inhibition
Introduction
Type 2 diabetes mellitus (T2DM), though historically recog-
nized as a disease of adulthood, has become increasingly com-
mon among children [1]. From 2001 to 2009, the prevalence
of T2DM among children aged between 10 and 19 in the USA
rose from 0.34 per 1000 to 0.46 per 1000, an overall increase
of 30.5% [2]. The prevalence is significantly higher in Native
Americans and African Americans than in other races [2].
Dipeptidyl peptidase-4 (DPP-4) is the primary enzyme in-
volved in the rapid in vivo degradation of the incretin hor-
mones, which play an important role in the pathogenesis of
T2DM [3]. The incretin hormones include glucagon-like pep-
tide-1 (GLP-1) and glucose-dependent insulinotropic peptide
(GIP), two peptides that exert major glucoregulatory functions
[3]. Released upon nutrient ingestion, these peptides stimulate
glucose-dependent insulin secretion and promote beta-cell
proliferation and cytoprotection [3, 4]. In patients with
T2DM, GIP is produced at normal levels with impaired
glucose-lowering action, while GLP-1 retains its
glucoregulatory activity despite diminished secretion [5, 6].
Thus, inhibition of DPP-4 activity increases plasma GLP-1
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levels, which in turn augments insulin secretion and reduces
blood glucose levels [7, 8].
Alogliptin is a DPP-4 inhibitor indicated as an adjunct to
diet and exercise to improve glycemic control in adults with
T2DM [9]. Clinical studies have demonstrated that alogliptin
produces rapid and sustained DPP-4 inhibition, improves both
postprandial and fasting plasma glucose, and reduces glycated
hemoglobin levels by approximately 0.5 to 1% after 12 to
26 weeks of treatment in adult T2DM patients [10–13].
Combined therapy using alogliptin with other non-DPP-4 in-
hibitor antidiabetic agents provides significantly better glyce-
mic control than monotherapy with any of these agents alone
[13–19].
The objectives of this study were to determine the pharma-
cokinetic (PK) and pharmacodynamic (PD) profiles of a single
dose of alogliptin 12.5 and 25 mg in pediatric (ages 10–17)
subjects with T2DM, and compare the pediatric PK/PD pro-
files with those in adult subjects with T2DM.
Methods
Study design
This phase 1, randomized, open-label, single-dose, multicen-
ter study (NCT00957268) was conducted in compliance with
the institutional review board regulations stated in the US
Code of Federal Regulations, Good Clinical Practice (GCP)
regulations and guidelines; the ethical principles originated
from the Declaration of Helsinki, the International
Conference on Harmonization E6 GCP guidance, and all ap-
plicable local regulations. Signed informed consent forms and
assent (if applicable) or certified translations of these forms (if
applicable) were obtained from each subject or the subject’s
legally acceptable representative before undergoing any study
procedures.
The study enrolled male and female T2DM patients who
were age-stratified into group 1 (children age 10 to <14 years),
group 2 (adolescents age 14 to <18 years), and group 3 (gen-
der- and race-matched adults age 18–65 years). A detailed
description of subject enrollment criteria is available in sup-
plemental materials.
A total of 24 pediatric subjects and 22 gender- and race-
matched adult subjects were enrolled in the study. Since
T2DM is uncommon among children, there were significant
enrollment challenges, particularly for subjects below 14 years
of age. As such, the number of enrolled subjects was based on
review of past PK studies of a similar nature and extensive
consultation of regulatory agencies. The final sample size was
a minimum number of subjects deemed sufficient to meet
study objectives. Statistical analysis was not performed to
determine the sample size.
The duration of the study was approximately 47 days,
consisting of screening (days −28 to −2), check-in (day −1),
a treatment period (days 1–4), and a follow-up phone call at
14 ± 1 days after study exit. Following screening for eligibil-
ity, enrolled subjects were admitted to the clinic on day −1. On
the first day of the treatment period, subjects in each pediatric
group (group 1 and group 2) were randomized in a 1:1 ratio to
receive a single, oral dose of alogliptin 12.5 or 25 mg, respec-
tively; all adult subjects (group 3) received a single dose of
alogliptin 25 mg. The study doses (12.5 and 25 mg) were
selected based on the results of phase 3 studies in adults.
Both dose levels were well tolerated in healthy adult subjects
and adult subjects with T2DM. A single dose was used be-
cause alogliptin exhibits linear kinetic properties. The study
drug was administered after an overnight fast of at least 8 h.
Subjects were released from the clinic in the evening on day 2
after the completion of all procedures and returned to the clinic
in the morning on days 3 and 4 for outpatient visits.
Approximately 14 days (14 ± 1 days) after the final visit
(study exit), subjects received a follow-up phone call to check
for adverse events (AEs)/serious AEs and concomitant medi-
cation uses that had occurred since study exit.
PK/PD bioanalytical analysis
For alogliptin concentration measurements, blood samples
were collected 1 h before dosing and 1, 2, 4, 8, 12, 16, 24,
48, and 72 h after dosing; urine samples were collected from
−12 to 0 h predose, and from 0 to 4, 4 to 8, 8 to 12, 12 to 24,
and 24 to 36 h postdose. Alogliptin plasma and urine concen-
trations were measured using liquid chromatography with tan-
dem mass spectrometry detection. Quantification of sample
alogliptin levels was performed according to calibration stan-
dards under strict quality controls (QC). A detailed description
of assay precision and accuracy is available in supplemental
materials.
For DPP-4 inhibition measurements, blood samples were
collected within 1 h before dosing and 2, 4, 8, 12, and 24 h
postdose. Sample DPP-4 inhibition was determined by a
fluorogenic method in 96-well plates under strict QCs. A de-
tailed description of assay precision and accuracy is available
in supplemental materials.
Assessments
PK parameters were derived using noncompartmental
methods with WinNonlin Enterprise, Version 6.3 (Pharsight
Corp., Cary, NC). The following plasma PK parameters were
evaluated: maximum observed plasma concentration (Cmax),
time to reach Cmax (Tmax), terminal elimination half-life (T1/2),
area under the plasma concentration-time curve from time 0 to
infinity (AUC0-inf), apparent clearance after oral administra-
tion (CL/F), and apparent volume of distribution (Vz/F).
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Evaluated urine PK parameters included renal clearance from
0 to 24 h postdose (CLr) and fraction of drug excreted in urine
from 0 to 36 h postdose (Fe).
PD parameters and individual DPP-4 inhibition were gen-
erated using WinNonlin Enterprise, Version 6.3. The follow-
ing PD parameters were evaluated: area under the plasma
effect-time curve from time 0 to 24 h postdose (AUEC0–24),
maximum observed effect (Emax), time to reach Emax (time to
Emax), and observed effect at 24 h postdose (E24).
The primary endpoints included the following plasma PK
parameters for alogliptin: Cmax, Tmax, T1/2, and AUC0-inf; the
secondary endpoints included the following PD parameters
for DPP-4 inhibition: AUEC0–24, Emax, time to Emax, and
E24. Additional endpoints included the following plasma and
urine PK parameters for alogliptin: CL/F, Vz/F, CLr, and Fe.
Safety measurements were incidence of AEs, clinical labora-
tory test results (hematology, serum chemistry, urinalysis,
fasting glucose, and blood glucose monitoring), vital sign
measurements, 12-lead electrocardiogram (ECG) results, and
physical examination findings.
Statistical analysis
Descriptive statistics (N, mean, standard deviation [SD], % coef-
ficient of variation,median,minimum, andmaximum)were used
to summarize plasma and urine PK and plasma PD parameters.
Descriptive statistics were also used to summarize AEs and
markedly abnormal vital sign and ECG results (N and % of
subjects), as well as clinical laboratory test results (hematology
and serum chemistry), vital sign results, body weights, and ECG
results (N, mean, SD, median, minimum, and maximum).
PK/PD modeling and simulations
Using adult and pediatric data from this study, an alogliptin
PK/PD model was developed to characterize the time course
of alogliptin concentrations and DPP-4 inhibition. To bridge
the adult and pediatric PK, the PK model included weight as
an initial covariate on clearance and volume of distribution
parameters, as shown in the following equation:
Pi ¼ Ppop⋅ WTiWT reference
 b
⋅eηi
where Pi is the individual PK parameter, Ppop is the population
PK parameter,WTi is the individual body weight,WTreference is
the reference body weight of 70 kg, b represents a power
function describing the relationship between weight and the
PK parameter (b = 0.75 for CL/F and b = 1 for Vz/F), and i
represents the intersubject variability with a mean = 0 and
variance =ω2. Other covariates, age (year), estimated glomer-
ular filtration rate (mL/min/1.73m2), race, and sex, were also
investigated as potential predicators of PK and PD parameters,
CL/F, Vz/F, absorption rate constant, and half-maximal con-
centration. Covariate analyses were performed using univari-
ate evaluation (p < 0.05,ΔOFV ≥3.84) followed by a stepwise
backward elimination approach (p < 0.001, ΔOFV ≥10.83).
The relationship between alogliptin concentrations and DPP-4
inhibition was described using a sigmoid Emax function in a
simultaneous PK/PD model as follows:
E ¼ E0 þ Emax*Conc
γ
EC50
γ þ Concγ þ ε
where E is DPP-4 inhibition, E0 is baseline response (fixed to
0), Emax is the predicted maximal response, Conc is predicted
alogliptin concentration, EC50 is the concentration resulting in
half-maximal response, γ is shape factor, and ε represents the
residual error with a mean = 0 and variance = σ2; separate
residual error terms were used for PK (alogliptin concentra-
tion) and PD (DPP-4 inhibition) measurements.
Model-based simulations were performed to project the
time course of alogliptin concentrations and DPP-4 inhibition
following repeated dosing of alogliptin 12.5 and 25 mg in
pediatric and adult populations. The simulations were based
on 100 hypothetical subjects in each pediatric or adult group.
For both groups, each subject’s body weight was sampled
from a log-normal distribution of body weight centered
around 95 kg (approximate study average), as body weights
overlapped considerably between pediatric and adult subjects.
T h e s imu l a t e d d a t a w e r e s umma r i z e d u s i n g
noncompartmental methods (e.g.,Cmax, area under the plasma




A total of 126 subjects were screened, among whom 46 sub-
jects were enrolled in the study and received the study drug.
Reasons for screening failure included not meeting entrance
criteria (66 subjects), voluntary withdrawal (4 subjects), lost to
follow-up (1 subject), and other (9 subjects). Of the enrolled
subjects, 9 were in group 1 (age 10 to <14 years) with 5
receiving alogliptin 12.5 mg and 4 receiving 25 mg; 15 were
in group 2 (age 14 to < 18 years) with 8 receiving alogliptin
12.5 mg and 7 receiving 25 mg; and 22 were in group 3 (age
≥18 years) receiving alogliptin 25 mg. One of the 46 enrolled
subjects (group 2, alogliptin 12.5 mg) discontinued on day 1
after receiving the study drug because blood samples could
not be drawn through the intravenous line, leaving 45 subjects
who completed all study visits.
Demographic information and baseline characteristics of
study participants are shown in Table 1. Most subjects were
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female and black or African American. Within each pediatric
group (group 1 and group 2), the mean age was similar be-
tween the two dose levels. The shortest duration of T2DMwas
53 days. Fifteen of 24 (62.5%) pediatric subjects and 17 of 22
(77.3%) adult subjects had medical history conditions, primar-
ily in the system organ class of surgical and medical proce-
dures. Almost all subjects had concurrent medical conditions,
primarily conditions associated with T2DM, such as obesity,
hyperlipidemia, and hypertension. Twenty of the 24 pediatric
subjects and 19 of the 22 adult subjects used concomitant
metformin, and 18 of the 24 pediatric subjects and 19 of the
22 adult subjects used other concomitant medications, primar-
ily medications used to treat hypertension or asthma/allergies.
PK data
Following a single oral administration of alogliptin, the mean
alogliptin plasma concentrations reached the maximum at 2 to
4 h and gradually declined thereafter through 24 h across all
three treatment groups for both 12.5- and 25-mg doses. The
linear and log-linear plots of mean plasma concentrations of
alogliptin vs time after a single dose of alogliptin are shown in
Fig. 1.
Themedian Tmax values of alogliptin after a single oral admin-
istration ranged from2 to4hacross all three treatment groups.The
mean Cmax and AUC0-inf values were similar between the two
pediatric groups (groups 1 and 2) but were 23 to 29% lower in all
pediatric subjects (groups 1 and2) than in adult subjects for the25-
mg dose. In each pediatric group, Cmax and AUC0-inf values in-
creased in a near-dose-proportional fashion between the 12.5- and
25-mgdoses.ThemeanCL/Fvalueswere similarbetween the two
pediatric groups (groups 1 and 2), butwere up to 37%higher in all
pediatric subjects (groups 1 and 2) compared with adult subjects.
Themean T1/2 andVz/F valueswere generally similar in pediatric
and adult subjects. Except for Cmax andAUC0-inf, mean values for
otherplasmaPKparametersappearedtobegenerallysimilaracross
pediatric groups and dose levels. The mean CLr and Fe values of
alogliptin were generally similar in pediatric and adult subjects for
both dose levels. The intersubject variability for all alogliptin plas-
ma and urine PK parameters was low (9–55% for plasma and 6–
33% for urine). The plasma and urine PK parameters following a
singleoraladministrationofalogliptin12.5mgor25mginchildren,
Table 1 Demographic information and baseline characteristics of study participants


























































Mean (SD) 86.62 (13.98) 98.90 (11.96) 116.28 (33.16) 103.71 (17.10) 92.25 (16.45)
BMI (kg/m2)
Mean (SD) 33.22 (4.62) 36.16 (3.42) 40.92 (9.19) 36.46 (6.76) 32.84 (4.49)
CrCla
Mean (SD) 111.46 (11.53) 114.84 (30.09) 124.88 (23.78) 112.63 (30.75) 87.69 (21.50)
Metformin (mg)
Mean (SD) 1000 (612.4)b 1667 (577.4)c 1583 (664.6)d 1300 (670.8)e 1346 (591.1)f
BMI, body mass index; CrCl, creatinine clearance; SD, standard deviation
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adolescents, and adults with T2DM are summarized in Table 2.
Regarding the impact of renal function on exposures, no correla-
tions were observed between dose-normalized AUC0-inf values of
alogliptin and creatinine clearance (CrCl) in pediatric and adult
subjects, despite the higher CrCl in pediatric subjects (CrCl 75.5–
167mL/min/1.73m2 inpediatric subjects vsCrCl53.6–140.2mL/
min in adult subjects). Scatter plots of dose-normalized AUC0-inf
valuesofalogliptin inchildren, adolescents, andadultswithT2DM
vsCrCl are shown in Fig. 2.
PD data
Administration of alogliptin resulted in rapid DPP-4 inhibition
in both pediatric and adult subjects with T2DM. The DPP-4
inhibition effect of alogliptin peaked at 2 to 4 h, reachingmore
than 80% inhibition, and gradually declined to at least 50% at
24 h across all three treatment groups for both the 12.5- and
25-mg doses. The mean DPP-4 inhibition vs time following a
single dose of alogliptin is shown in Fig. 3.
The median time to Emax after a single dose of alogliptin
ranged from 2 to 4 h across all three treatment groups. Themean
values for Emax were similar between the pediatric and adult
subjects for the 25-mg dose. Mean values for AUEC0–24 and
E24were lower in all pediatric subjects than in the adult subjects.
Withinpediatric groups, themeanvalues forEmaxwere lower for
the 12.5-mg dose (approximately 80%) than for the 25-mg dose
(approximately 90%); the mean values for AUEC0–24 were ap-
proximately 8 and 19% lower for the 12.5-mg dose than for the
25-mg dose in group 1 and group 2, respectively. Within each
dose level, DPP-4 inhibition appeared to be generally similar
between groups 1 and 2. The intersubject variability for PD pa-
rameters of DPP-4 inhibition was very low (≤20%). The PD
parameters of DPP-4 inhibition following a single oral adminis-
tration of alogliptin 12.5 or 25 mg in children, adolescents, and
adults with T2DM are summarized in Table 3.
PK/PD modeling and simulations
The PK/PD model consists of a two-compartment model with
first-order absorption and elimination and body weight effects
on clearance and volume parameters, plus a direct Emax model
linking plasma alogliptin concentrations to DPP-4 inhibition.
This model adequately described the PK/PD data in both pe-
diatric and adult subjects with T2DM, as demonstrated by the
goodness-of-fit test and visual predictive check (Supplemental
Figs. 1 and 2). The model parameters were estimated with
good precision (Supplemental Table 1). Although separate
values for absorption rate constant, oral clearance, and EC50
were reported for pediatric and adult subjects, the differences
were not considered clinically relevant. Except for body
weight, no additional covariates were retained in the model.
Following repeated doses of alogliptin, the simulated Cmax
and AUC0-tau values of alogliptin 25 mg were higher than those
of alogliptin 12.5 mg in adult and pediatric subjects. The simu-
latedadultexposurewasconsistentwith that fromaphase1study
inadult subjectswithT2DMreceiving25mgalogliptin [10].The
simulated Cmax and AUC0-tau values were generally lower in
pediatric subjects than in adult subjects. Despite these modest
differences in exposure to alogliptin, the simulated Emax values
were similar between pediatric and adult subjects, which is con-
sistent with the study results and previously reported PD activity
inadultT2DMsubjects [10].Withinpediatricsubjects,simulated
DPP-4 inhibition levels at steady state through 24 h postdose
were 65.2 and75.1% following alogliptin 12.5 and25mgdoses,
respectively.Thesimulatedalogliptinplasmaconcentrationsand
DPP-4 inhibition vs time after repeated doses of alogliptin are
shown in Fig. 4. The simulated plasma PK and PD parameters
following repeated oral administrations of alogliptin are summa-
rized in Table 4.
Fig. 1 The a linear and b log-linear plots of mean plasma concentrations
of alogliptin vs time after a single dose of alogliptin. ALO, alogliptin
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Safety
During the entire study period, 20 subjects experienced 36
treatment-emergent AEs (TEAEs; Table 5). Most of the TEAEs
weremild.Onemoderate(jointswelling)AEwasexperiencedby
one subject, and one severe (headache) AE was experienced by
one subject in group 3 receiving alogliptin 25 mg; both were
considered by the investigators to be unrelated to the study drug.
Themost frequently reported TEAEs (occurred in ≥2 subjects in
any dose level in any group)were headache, nausea, fatigue, and
abdominalpain.NoAEs led tostudydrugdiscontinuationandno
deaths occurred. An overview of TEAEs is provided in Table 5.
One postdose abnormal serum chemistry test result (in-
creased blood creatine kinase) in one subject (group 2
receiving alogliptin 25 mg), two postdose abnormal hematol-
ogy test results in two subjects (decreased neutrophil count in
group 1 receiving alogliptin 12.5mg and decreased hematocrit
and hemoglobin in group 2 receiving alogliptin 25 mg), and
one postdose abnormal vital sign result (increased body tem-
perature) in one subject (group 1 receiving alogliptin 12.5 mg)
were reported as TEAEs. All these TEAEs were mild in in-
tensity. No abnormal ECG result was reported as a TEAE.
Discussion
Followingasingleoral administrationofalogliptin12.5or25mg
tablets to children, adolescents, and adults with T2DM, the
Table 2 The plasma and urine pharmacokinetic parameters following a single oral administration of alogliptin 12.5 or 25 mg in children, adolescents,
and adults with type 2 diabetes mellitus









































































































ALO, alogliptin; AUC0-inf, area under the plasma concentration-time curve from time 0 to infinity;CL/F, apparent clearance after oral administration;CLr,
renal clearance from 0 to 24 h postdose; Cmax, maximum observed plasma concentration; CV, coefficient of variation; Fe, fraction of drug excreted in
urine from 0 to 36 h postdose; T1/2, terminal elimination half-life; Tmax, time to reach Cmax; Vz/F, apparent volume of distribution
aN = 4 for CLr and Fe
bMedian is presented for Tmax instead of mean
cMinimum, maximum is presented for Tmax instead of %CV
Fig. 2 Scatter plots of dose-
normalized AUC0-inf values of
alogliptin in children,
adolescents, and adults with type
2 diabetes mellitus vs creatinine
clearance. AUC0-inf, area under
the plasma concentration-time
curve from time 0 to infinity
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plasma and urine PK of alogliptin appeared to be generally sim-
ilar between the two age groups of pediatric subjects. Within
pediatric subjects, dose-proportional increases in mean Cmax
and AUC0-inf values of alogliptin were observed between the
12.5- and 25-mg doses. The median Tmax values were similar
across the pediatric and adult groups, indicating similar rates of
appearanceof alogliptin inplasma.ThemeanCmax andAUC0-inf
valuesof alogliptinwere23 to29%lower in all pediatric subjects
thaninadult subjects for thealogliptin25mgdose,suggestingthe
extent of exposure was lower in pediatric subjects than in adult
subjects. Because CrCl, a measure of renal function, was higher
in pediatric subjects (CrCl 75.5–167 mL/min/1.73 m2) than in
adult subjects (CrCl 53.6–140.2mL/min), the slight decreases in
CmaxandAUC0-inf inpediatric subjectsmaybedue to the slightly
higher renal function in these subjects. ThemeanCL/F values of
alogliptin were up to 37% higher in pediatric subjects than in
adult subjects. The other plasma and urine PK parameters of
alogliptin (Vz/F, T1/2, Clr, Fe) were generally similar across the
pediatric and adult subject groups.
Administration of alogliptin resulted in rapidDPP-4 inhibition
in both pediatric and adult subjects with T2DM. Although the
extent of exposure was lower in pediatric subjects than in adult
subjects as demonstrated by the mean Cmax and AUC0-inf values,
the levels of DPP-4 inhibition—indicated by the mean Emax and
AUEC0–24 values—were similar between the two populations.
This is particularly true for the adolescent group (age 14 to
<18 years), in which the Emax and AUEC0–24 values were almost
identical to those in the adult group.Within pediatric subjects, the
mean Emax values were approximately 80 and 90% for alogliptin
12.5 and 25 mg, respectively; the mean AUEC0–24 values were
approximately 8 and 19% lower for the 12.5-mg dose than for
the 25-mg dose in group 1 and group 2, respectively.Within each
dose level, DPP-4 inhibition appeared to be generally similar in
groups 1 and 2. Model-simulated alogliptin PK and PD param-
eters were similar to those observed in this study. Single doses of
alogliptin 12.5 and 25 mg were well tolerated in pediatric and
adult subjects. No dose relationship was observed in the percent-
ages of pediatric subjects who had TEAEs, and the incidence of
TEAEs was lower in pediatric subjects who received alogliptin
25 mg than in adult subjects.
The majority of the study subjects were African American;
pediatric T2DM is particularly prevalent among African
Americans [2], which limited the availability of subjects of other
races. Since race has no clinically meaningful effect on alogliptin
PK in adults [9], our study results are likely to be applicable to
pediatric patients of other races. However, this speculation needs
to be confirmed in future larger pediatric trials including more
non-African American subjects.
This study excluded subjects with renal impairment or hyper-
tension, two common comorbidities of T2DM. Because
alogliptin primarily relies on renal excretion [20], renal function
Table 3 The pharmacodynamic parameters of DPP-4 inhibition following a single oral administration of alogliptin 12.5 or 25 mg in children,
adolescents, and adults with type 2 diabetes mellitus
Treatment Group Number Time to Emax (hr) Emax (%) AUEC0–24 (%·hr) E24 (%)
Median (Min, Max) Mean (%CV) Mean (%CV) Mean (%CV)
ALO 12.5 mg 10 to <14 years 5 4.05 (2.00, 4.08) 83.7 (5) 1570 (7) 52.0 (20)
14 to <18 years 7 4.00 (2.00, 4.03) 81.6 (7) 1558 (12) 55.4 (16)
ALO 25 mg 10 to <14 years 4 2.08 (2.00, 4.00) 89.3 (3) 1699 (4) 57.4 (9)
14 to <18 years 7 4.00 (3.97, 4.12) 90.4 (2) 1854 (3) 70.4 (8)
Adults 22a 2.00 (2.00, 4.07) 92.7 (2) 1890 (4) 72.8 (7)
ALO, alogliptin; AUEC0–24, area under the plasma effect-time curve from time 0 to 24 h postdose; CV, coefficient of variation; DPP-4, dipeptidyl
peptidase-4; E24, observed effect at 24 h postdose; Emax, maximum observed effect
aN = 21 for E24
Fig. 3 The mean DPP-4 inhibition vs time following a single dose of
alogliptin. ALO, alogliptin; DPP-4, dipeptidyl peptidase-4
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is a major determinant of drug exposure. In a PK study in adults,
exposure to alogliptin increased approximately 1.7-fold in pa-
tients with mild renal impairment, 2.1-fold in patients with mod-
erate renal impairment, and 3.8-fold in patients with end stage
renal disease (ESRD), relative to healthy subjects [20].
Therefore, alogliptin prescribing information recommends a
50% dose reduction for adult patients with moderate renal im-
pairment (CrCl ≥30 to <60 mL/min) and a further 50% dose
reduction for patients with severe renal impairment (CrCl ≥15
to <30 mL/min) or ESRD (CrCl <15 mL/min or requiring he-
modialysis) [9]. However, in clinical studies, alogliptin displayed
similar efficacy and safety profiles between patients with renal
impairment and normal renal function [9]. Additionally, this
study did not evaluate the effect of hypertension on the PD of
alogliptin. In contrast to renal function, an experimentally proven
determinant of drug exposure, hypertension is not expected to
have a significant influence on dose setting and, therefore, has
not been extensively studied. There is very little information
regarding the effect of hypertension on PD of alogliptin.
However, alogliptin was shown to lower blood pressure in pa-
tients with T2DM [21].
In addition, in an alogliptin cardiovascular safety trial inwhich
83% of patients had hypertension, alogliptin demonstrated a sim-
ilar rate of major adverse cardiovascular events to that of placebo
in these patients [9]. Given the minor impact of hypertension on
alogliptin exposure and safety and the low incidence of this
condition among children, not assessing the effect of hyperten-
sion on DPP-4 inhibition is unlikely to affect the purpose of this
study. As a phase 1 study and the first study of alogliptin in
pediatric patients, this study had a small sample size. The purpose
of the study was to establish a basic dose for future phase 3
pediatric studies, and the inclusion criteria only allowed pediatric
subjects without clinically significant disorders other than T2DM
and adult subjects without clinically significant disorders other
than T2DM and controlled hypertension. As such, eliminating
the interferences of comorbidities on alogliptin PK profile main-
tains analysis sensitivity for this small study. Based on adult PK
data, we speculate that renal function may have a similar impact
on alogliptin PK in children. This needs to be tested in future
larger pediatric studies including subjects with renal impairment.
Based on the PK and PD data and model simulations, pe-
diatric subjects with T2DM require the 25-mg dose of
alogliptin to achieve alogliptin exposures and DPP-4 inhibi-
tion similar to those in adults with T2DM. The 25-mg dose in
Fig. 4 The simulated alogliptin plasma concentrations and DPP-4 inhibition vs time after a single dose of alogliptin.DPP-4, dipeptidyl peptidase-4. The
solid line is the median; the shaded region is the 90% prediction interval
Tab le 4 The s imu la t ed p l a sma pha rmacok ine t i c and












Pediatric 12.5 55.6 729.5 66.0
25 112.2 1400.2 75.8
Adulta 12.5 73.4 777.2 70.5
25 147.7 1575.1 79.9
AUC0-tau area under the plasma concentration-time curve from time 0 to
the end of the dosing period; Cmax, maximum observed plasma concen-
tration; E24, observed effect at 24 h postdose
a In the phase 1 study in adults with T2DM, the Cmax was 152.8 ng/mL,
AUC0-tau was 1473.7 ng·h/mL, and E24 was 81.8%
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adolescents best approximates the DPP-4 inhibition in adults
following 25-mg dose administration, despite some modest
differences in alogliptin PK (simulated median steady state
Cmax and AUC0-tau values in adolescents was 24 and 11%
lower, respectively, relative to adults) between the two popu-
lations. The DPP-4 inhibition in adolescents receiving a 12.5-
mg dose was considered suboptimal, since efficacy requires
steady state trough DPP-4 inhibition of approximately 80%
[22]. Therefore, the 25-mg dose that has shown to be safe and
efficacious in adults should be a suitable dose for evaluation in
the pediatric phase 3 program. It should be noted, however,
that alogliptin is not approved for use in pediatric patients with
T2DM.
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